Form 4: Avidity Biosciences Director Edward Kaye Receives Equity Compensation Grant

Avidity Biosciences, Inc. Director Edward M. Kaye, MD, was granted 6,692 restricted stock units and options to purchase 10,034 shares of common stock as part of his compensation.

Summary

• Edward M. Kaye, MD, a Director of Avidity Biosciences, Inc. (RNA), reported changes in his beneficial ownership of company securities.
• On June 10, 2025, Dr. Kaye acquired 6,692 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0 per share.
• These RSUs represent a contingent right to receive one share of common stock each and are set to vest in full on the earlier of June 10, 2026, or the Issuer's 2026 annual meeting of stockholders, contingent on his continuous service.
• Additionally, on June 10, 2025, Dr. Kaye was granted stock options to purchase 10,034 shares of Common Stock with an exercise price of $33.62 per share.
• These stock options will also vest in full on the earlier of June 10, 2026, or the Issuer's 2026 annual meeting of stockholders, subject to his continuous service.
• The stock options have an expiration date of June 9, 2035.
• Following these transactions, Dr. Kaye beneficially owns 6,692 shares of Common Stock and 10,034 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing reports a standard equity compensation grant to a director, aligning their interests with shareholders, which is generally viewed positively as a mechanism for long-term incentive and retention.

Positives

• The grant of restricted stock units and stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for attracting and retaining experienced board members like Dr. Kaye.

Negatives

• The vesting of both RSUs and stock options is contingent on Dr. Kaye's continuous service to the Issuer, meaning the benefits are not immediate or guaranteed if service ceases.

Risks

• The value of the granted RSUs and stock options is subject to the future performance of Avidity Biosciences' common stock.
• The vesting of the equity awards is conditional on the reporting person's continuous service to the Issuer through June 10, 2026, or the 2026 annual meeting of stockholders.

Future Outlook

The equity grants are structured to incentivize the director's continued service and contribution to Avidity Biosciences until at least June 2026, aligning future performance with compensation.

Industry Context

Equity compensation, including RSUs and stock options, is a common and widely accepted practice in the biotechnology and pharmaceutical industries to compensate directors and executives, aligning their long-term interests with company performance and shareholder value.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: No direct impact on general employees is indicated by this filing, but it reflects the company's compensation philosophy for its leadership.

Next Steps

• Continued service of Edward M. Kaye, MD, to Avidity Biosciences, Inc. to meet vesting conditions for RSUs and stock options.
• Vesting of 6,692 RSUs and 10,034 stock options on the earlier of June 10, 2026, or the Issuer's 2026 annual meeting of stockholders.

Key Dates

Keywords

Avidity Biosciences, RNA, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Option, Equity Compensation, Director Compensation, Beneficial Ownership